BMRN (biomarin.com) Prakiraan pendapatan perusahaan

BioMarin Pharmaceutical Inc. - logo grafis emiten BMRN

BioMarin Pharmaceutical (BMRN) develops exclusive medications for rare pathologies, allowing the company to independently determine high therapy costs. Current sales forecasts confirm this trend, with the 3.69 level serving as a critical mark. Orphan drug status protects the business from competition, while a monopoly asset portfolio guarantees a stable long-term cash flow.

BMRN - Pendapatan mangsa ngarep perusahaan BioMarin Corp ing rentang 04.07.2022 - 16.11.2026

Rincian metrik keuangan lan pasar BioMarin Corp (BMRN)

- rega saiki lan proyeksi nilai saham:
Analisis fundamental perusahaan:biomarin.com
Produk mawa merek BioMarin Pharma

BioMarin Pharmaceutical (BMRN) maintains a monopoly position in the treatment of ultra-rare diseases, allowing the company to exercise pricing power and minimize market risks. By analyzing the firm's estimated sales volume, an investor can observe the market's real-time revaluation of future cash flows and the resilience of supply chains, making it possible to distinguish fundamental revenue growth from temporary fluctuations and confirm the asset's long-term reliability.

Analisis perusahaan pesaing

Volume dodolan mangsa ngarep perusahaan VRTX (Vertex)|ALNY (Alnylam Pharmaceuticals, Inc.) - Pendapatan mangsa ngarep perusahaan|Prakiraan pendapatan perusahaan Insmed INSM|UTHR (United Therapeutics Corp.) - Pendapatan sing dikarepake perusahaan|BridgeBio Pharma, Inc. - Prakiraan volume dodolan|BGM - Prakiraan volume dodolan|COGT: Prakiraan volume dodolan|Xeris Biopharma Holdings, Inc. (XERS) - Prakiraan volume dodolan|Prakiraan pendapatan perusahaan Keros Pharma|ARCT: Pendapatan mangsa ngarep perusahaan|Prakiraan pendapatan perusahaan etonpharma.com (ETON)|Volume dodolan mangsa ngarep perusahaan Kamada Ltd. KMDA|Prakiraan volume dodolan FULC (fulcrumtx.com)|Prakiraan volume dodolan Abeona ABEO|MREO - Prakiraan pendapatan perusahaan|Pendapatan mangsa ngarep perusahaan PLX (Protalix BioTherapeutics, Inc)|Pliant Therapeutics Inc (PLRX) - Prakiraan pendapatan perusahaan|Pendapatan sing dikarepake perusahaan APLT (appliedtherapeutics.com)|RNTX (Rein Therapeutics Inc.) - Prakiraan volume dodolan|Prakiraan pendapatan perusahaan GELS|Volume dodolan mangsa ngarep perusahaan AYTU (aytubio.com)|Volume dodolan mangsa ngarep perusahaan Chemomab Therapeutics Ltd CMMB|Prakiraan volume dodolan SRXH (SRx Health Solutions Inc.)|Pendapatan mangsa ngarep perusahaan PLRZ|AEZS - Prakiraan pendapatan perusahaan|Pendapatan mangsa ngarep perusahaan CYTH (CTD Holdings)|INZY: Prakiraan volume dodolan|Pendapatan sing dikarepake perusahaan RPHM (Reneo Pharma)|Prakiraan pendapatan perusahaan cosciensbio.com